Current deal trends and prospects in therapeutic antibodies

《Current deal trends and prospects in therapeutic antibodies》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、CurrentdealtrendsandprospectsintherapeuticantibodiesAsatherapeutic,monoclonalantibodiesarecomingofageinthatinnovativecompanieshavebeenpersistentinimprovinguponanalreadyeffectivetherapeuticdevelopmentstrategy.Dealmakingintheantibodysectorremainsbuoyantdespitetheimpactofthedownturnfeltbyothersectors.B

2、YIORDANISARZIMANOGLOUWITHSUZANNEELVIDGEherapeuticmonoclonalantibodiesarebigbusiness.In2012,therewere5antibod-Tiesinthetop20drugsbysales1,andatleast8areforecasttoenterthemarketperyear.Thiswilldrivetheglobalmarketfromapproxi-mately$44billionin2011tonearly$58billionSource:CurrentAgreements2013in20162.A

3、nactivepipelinefeedsthisgrowth;forexample,inJanuary2013therewere302companiespluspartnersdeveloping591anti-bodydrugsin1,377developmentalprojectsincancer3.Figure1:Recentdealsbyyear(January2007–February/March2013)Themarketpotentialofthesedrugsmakestherapeuticantibodiesaveryattractivetarget$80  forbioph

4、armaceuticaldealmaking,especiallyasanumberhaveachievedblockbusterstatus$67.0  $70  (annualglobalsalesexceeding$1billion).Licensingdealsarevitaltokeeplicensors'$60  fundingstreamsbuoyantandtoensurethatlicensees'pipelinesarefilled.Demonstratingthe$50  Source:DeloitteRecapLLC$42.0  latterneed,ananalysi

5、sofdrugsalesbetween$40.0  $39.0  2008and2013(estimatedfigures)from14$40  Average  (million)  largepharmaceuticalcompaniesshowedthat$31.0  Median  (million)  lessthanhalfoftheincomefromdrugswithfore-$30  castedsalesofatleast$500millioncamefrom$22.0  productsthatwerediscoveredanddeveloped$20  entirely

6、in-house4.$13.0  $10  $7.5  Doingthedeal:numberof$2.4  $2.0  monoclonalantibodiesdeals$0  Phase  III  Phase  II  Phase  I  Preclinical  Lead  stage  AccordingtotheCurrentAgreementsdealsdatabase,thenumberofdealsoverallrelatingtoantibodieshasremainedsteadyoverthepastFigure2:Upfrontcashandequitypayment

7、ssixyears(Fig.1).Theconsistency,despitethevagariesoftheincreases.forward,andtobringcheaperandmoreeffectiveeconomicclimate,confirmstheimportanceLookingattheRecapdatafordealssignedantibody-baseddrugstot